BioLineRx (NASDAQ:BLRX) Posts Quarterly Earnings Results, Beats Estimates By $0.28 EPS

BioLineRx (NASDAQ:BLRXGet Free Report) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.28, Zacks reports. The firm had revenue of $6.86 million during the quarter, compared to the consensus estimate of $0.34 million. During the same period in the previous year, the company posted ($0.15) EPS.

BioLineRx Stock Down 3.3 %

Shares of BLRX traded down $0.02 on Wednesday, hitting $0.70. 77,336 shares of the stock traded hands, compared to its average volume of 383,838. The company has a market capitalization of $55.56 million, a PE ratio of -0.78 and a beta of 1.50. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.47 and a current ratio of 1.53. The business has a 50 day simple moving average of $0.76 and a 200 day simple moving average of $1.17. BioLineRx has a one year low of $0.55 and a one year high of $2.53.

Analyst Ratings Changes

Several brokerages have commented on BLRX. HC Wainwright restated a “buy” rating and issued a $21.00 price objective on shares of BioLineRx in a report on Wednesday. StockNews.com raised shares of BioLineRx to a “sell” rating in a research note on Tuesday, April 23rd.

Check Out Our Latest Report on BLRX

About BioLineRx

(Get Free Report)

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.

Further Reading

Earnings History for BioLineRx (NASDAQ:BLRX)

Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.